TAIPEI (Taiwan News) — Far Eastern Memorial Hospital is set to become the first medical institution in Taiwan to administer ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to ...

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

Jim Herlihy, a regional spokesman for the Alzheimer’s Association, will tell you that Kocherhans finds himself in good, if ...

Leqembi (lecanemab-irmb) is a prescription drug that’s used to treat Alzheimer’s disease. It comes as a liquid solution that healthcare professionals administer as an intravenous (IV ...

Leqembi (lecanemab-irmb) has potential interactions with other medications. These interactions could cause harmful effects. An interaction can occur because one substance causes another substance ...

Aaron is one of at least seven people who have died in the US from symptoms linked to the drug Leqembi over the past two years, according to a Bloomberg review of federal records obtained through ...